Prosigna is powered by nCounter® digital technology1
Prosigna sets the standard for reliable, reproducible results1,2
Since 2008, NanoString’s nCounter technology has been changing the way researchers study gene expression. Now we are applying the same technology that has led to hundreds of peer-reviewed publications to breast cancer diagnostics. Fully automated and easy to use, the nCounter-based Prosigna assay allows you to quickly and accurately analyze breast cancer gene expression and make informed treatment decisions.
Strong analytical performance: sensitive, precise, and quantitative
Single-tube multiplexing: all 50 Prosigna genes are measured in a single reaction—no amplification required
Easy to use: fully automated, intuitive user interface
Nature Biotechnology features the nCounter technology
Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
References: 1. Prosigna [Package Insert]. Seattle, WA: NanoString Technologies, Inc; 2013. 2. Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens [published online ahead of print March 13, 2014]. BMC Cancer. doi:10.1186/1471-2407-14-177. 3. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317-325.
Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy.